« Kroger recalls pistachios in 31 states
Special Committee On Aging Discusses The Alzheimer’s Report On Ways To Improve Care, USA »

ACC: Early Eptifibatide Not Beneficial in Coronary Syndrome

March 30th, 2009 by admin

Zoloft Children Overdose Blood Pressure Meds And Viagra Does Paxil And Dexatrim Max Interact Prednisone Damage Heart Cipro Ear Drops Use In Dogs Medicamento Nexium Can Lamictal Cause Tremors Sulfur Antabuse Is Hgh Sold In Stores Soma Safe Bed Meloxicam Tbts Mobic Augmentin 875-125 Dosage All Natura Viagra Omnicef Induced Fever Pregnancy And Dilantin Transsexual Breast Augmentation Desyrel 50mg Effexor And Relax Ventolin Evohaler Clomid Testicular Axis Allegra Lead Investigator Prednisone High Dose Long Term How Good Is Fosamax Maximum Dose Of Aricept Paxil Lawsuits Delaware Norvasc Adverse Effects Osteoarthritis Paxil Viagra Online Ordering Flomax Generic Name Flonase Leukopenia Dilantin Blood Level Ultram Picture Thunderbird Samaritan Coumadin Clinic Allergic To Prozac Artist Michael Soma Differin Mall Toronto Synthroid And Calcium Statistics Of Weight Gain On Paxil Lexapro Image Breast Enhancement Archive Zocor Pros Cons Conditions Sinequan Can Be Prescribed For Active Ingredients In Motrin Arimidex Men Excess Estrogen Osteoporosis Adhd Lexapro Effexor Prilosec United Kingdom Drug Interactions With Prozac Natural Viagra China Prednisone Azathioprine Weaning Off Of Prozac And Pregnancy

In patients with acute coronary syndromes without ST-segment elevation, early use of eptifibatide does not lead to better outcomes compared to delayed use and may be associated with an increased risk of bleeding that necessitates transfusion, according to a study published online March 30 in the New England Journal of Medicine to coincide with the American College of Cardiology’s 58th Annual Scientific Session held March 29 to 31 in Orlando, Fla.

More: continued here

This entry was posted on Monday, March 30th, 2009 at 6:03 pm and is filed under Senior Health News. You can follow any responses to this entry through the RSS 2.0 feed. You can leave a response, or trackback from your own site.

Leave a Reply